JAG-1 (188-204) 1mg
CDDYYYGFGCNKFCRPR-acid
Description
Application Data
Description
-
Jagged – 1 is a cell surface ligand for in the Notch pathway. JAG-1(188-204)
Application Data
-
Material Safety Data Sheet (MSDS)Catalogue number crb1001588j Molecular Weight 2105.9 Sequence (one letter code) CDDYYYGFGCNKFCRPR-acid
Sequence (three letter code) H-Cys-Asp-Asp-Tyr-Tyr-Tyr-Gly-Phe-Gly-Cys-Asn-Lys-Phe-Cys-Arg-Pro-Arg-OH
Purity >95% Storage -20°C References Grochowski et al., (2016). Jagged1 (JAG1): Structure, expression, and disease associations. Gene. 576(1 Pt 3): 381-4. PMID: 26548814
Pandya et al., (2016). PKCα Attenuates Jagged-1-mediated Notch Signaling in ErbB-2 positive Breast Cancer to Reverse Trastuzumab Resistance. Clin Cancer Res. 22(1): 175. PMID: 26350262
Manufactured in: United Kingdom JAG-1(188-204). Jagged – 1 is a cell surface ligand for in the Notch pathway. Notch receptors and ligands are present on the extracellular service of cells and require cell-cell contact for engagement. Ligand binding to Notch receptors results in the proteolytic cleavage of membrane-bound Notch receptors, thus allowing the intercellular region to be transported to the nucleus and become a transcriptional activator. The ligand-induced Notch activation is regulated by E3 ubiquitin ligases, Mindbomb1 (Mib-1) and Neuralized.
JAG1 is widely expressed throughout mammalian development, across many tissues and developmental stages. Notch signalling plays a critical role in cellular fate determination including muscle cell differentiation, neurogenesis, and the development of the sensory regions of the inner ear; heart; kidney; eye; lung and other tissues.
Jag-1 has been implicated in breast; cervical; colorectal; endometrial; gastric; head and neck; ovarian; hepatocellular; lung; pancreatic; prostate, and kidney and adrenocortical cancers, leukemia and lymphoma. Co-overexpression of Notch-1 and Jagged-1 predicts the poorest overall cancer survival. JAG1 mutations have also been associated Alagille syndrome.